Literature DB >> 22573456

Depression and anxiety symptoms among women who carry the FMR1 premutation: impact of raising a child with fragile X syndrome is moderated by CRHR1 polymorphisms.

Jessica Ezzell Hunter1, Mary Leslie, Gloria Novak, Debra Hamilton, Lisa Shubeck, Krista Charen, Ann Abramowitz, Michael P Epstein, Adriana Lori, Elisabeth Binder, Joseph F Cubells, Stephanie L Sherman.   

Abstract

The fragile X mental retardation gene, FMR1, contains a polymorphic CGG repeat in the 5'-untranslated region of exon 1. Once unstable, this repeat is capable of expansion across generations. Women who carry a premutation allele (55-199 repeats) are at risk of passing on a full mutation allele (>200 repeats) to their offspring. A full mutation leads to the most common form of inherited intellectual disability, fragile X syndrome (FXS). Mounting evidence suggests that premutation carriers may be vulnerable to symptoms of anxiety and depression. The goal of this study was to test the hypothesis that among women who carry a premutation, the stress of raising a child with FXS would be moderated by genetic factors influencing endogenous cortisol responses, which could in turn modulate anxiety and depression symptoms. To this end, we genotyped single nucleotide polymorphisms (SNPs) at the corticotrophin releasing hormone receptor 1 locus (CRHR1) in 460 women. Participants completed self-report questionnaires assessing symptoms of depression [Centers for Epidemiological Studies Depression Scale (CESD)], anxiety [State-Trait Anxiety Inventory (STAI) and Social Phobia and Anxiety Inventory (SPAI)], and mood [Positive and Negative Affect Schedule (PANAS)]. Results indicate a statistically significant interaction between CRHR1 genotype and the status of raising a child with FXS to predict social anxiety symptoms reported on the SPAI (rs7209436, P = 0.0001). Our data suggest that genetic variants in CRHR1 that associate with differential cortisol activation may also modulate levels of anxiety related to the stress of raising a child with FXS among women who carry an FMR1 premutation.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22573456      PMCID: PMC3696495          DOI: 10.1002/ajmg.b.32061

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  51 in total

1.  Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.

Authors:  David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-11-05       Impact factor: 3.568

2.  Association of FMR1 repeat size with ovarian dysfunction.

Authors:  A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

3.  Expanded clinical phenotype of women with the FMR1 premutation.

Authors:  Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2008-04-15       Impact factor: 2.802

4.  Impact of the Fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated Tremor/Ataxia syndrome: a controlled study.

Authors:  Cary S Kogan; Jeremy Turk; Randi J Hagerman; Kim M Cornish
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-09-05       Impact factor: 3.568

5.  FMR1 protein: conserved RNP family domains and selective RNA binding.

Authors:  C T Ashley; K D Wilkinson; D Reines; S T Warren
Journal:  Science       Date:  1993-10-22       Impact factor: 47.728

6.  Evidence of depressive symptoms in fragile-X syndrome premutated females.

Authors:  Laia Rodriguez-Revenga; Irene Madrigal; Montserrat Alegret; Mónica Santos; Montserrat Milà
Journal:  Psychiatr Genet       Date:  2008-08       Impact factor: 2.458

7.  Examination of reproductive aging milestones among women who carry the FMR1 premutation.

Authors:  E G Allen; A K Sullivan; M Marcus; C Small; C Dominguez; M P Epstein; K Charen; W He; K C Taylor; S L Sherman
Journal:  Hum Reprod       Date:  2007-06-22       Impact factor: 6.918

8.  Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene.

Authors:  Rebekah G Bradley; Elisabeth B Binder; Michael P Epstein; Yilang Tang; Hemu P Nair; Wei Liu; Charles F Gillespie; Tiina Berg; Mark Evces; D Jeffrey Newport; Zachary N Stowe; Christine M Heim; Charles B Nemeroff; Ann Schwartz; Joseph F Cubells; Kerry J Ressler
Journal:  Arch Gen Psychiatry       Date:  2008-02

9.  Fragile X syndrome: diagnostic and carrier testing.

Authors:  Stephanie Sherman; Beth A Pletcher; Deborah A Driscoll
Journal:  Genet Med       Date:  2005-10       Impact factor: 8.822

Review 10.  Is there evidence for neuropsychological and neurobehavioral phenotypes among adults without FXTAS who carry the FMR1 premutation? A review of current literature.

Authors:  Jessica Ezzell Hunter; Ann Abramowitz; Michele Rusin; Stephanie L Sherman
Journal:  Genet Med       Date:  2009-02       Impact factor: 8.822

View more
  18 in total

1.  FMR1 genotype interacts with parenting stress to shape health and functional abilities in older age.

Authors:  Marsha Mailick; Jinkuk Hong; Jan Greenberg; Leann Smith Dawalt; Mei Wang Baker; Paul J Rathouz
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-04-13       Impact factor: 3.568

Review 2.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

3.  Improving Health Education for Women Who Carry an FMR1 Premutation.

Authors:  Whitney Espinel; Krista Charen; Lillie Huddleston; Jeannie Visootsak; Stephanie Sherman
Journal:  J Genet Couns       Date:  2015-07-16       Impact factor: 2.537

4.  High rates of comorbid depressive and anxiety disorders among women with premutation of the FMR1 gene.

Authors:  Heather A Kenna; Molly Tartter; Scott S Hall; Amy A Lightbody; Quynh Nguyen; C Paula de los Angeles; Allan L Reiss; Natalie L Rasgon
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2013-09-03       Impact factor: 3.568

5.  Health knowledge of women with a fragile X premutation: Improving understanding with targeted educational material.

Authors:  Liana Smolich; Krista Charen; Stephanie L Sherman
Journal:  J Genet Couns       Date:  2020-01-30       Impact factor: 2.537

Review 6.  Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome.

Authors:  Randi Hagerman; Paul Hagerman
Journal:  Lancet Neurol       Date:  2013-08       Impact factor: 44.182

7.  Psychosis and catatonia in fragile X: Case report and literature review.

Authors:  Tri Indah Winarni; Andrea Schneider; Neera Ghaziuddin; Andreea Seritan; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2015-08

8.  Trajectory and Predictors of Depression and Anxiety Disorders in Mothers With the FMR1 Premutation.

Authors:  Jane E Roberts; Bridgette L Tonnsen; Lindsay M McCary; Amy L Ford; Robert N Golden; Donald B Bailey
Journal:  Biol Psychiatry       Date:  2015-07-31       Impact factor: 13.382

9.  The effects of optimism, religion, and hope on mood and anxiety disorders in women with the FMR1 premutation.

Authors:  E P Lowell; B L Tonnsen; D B Bailey; J E Roberts
Journal:  J Intellect Disabil Res       Date:  2017-10

10.  Developmental and behavioral pediatricians' attitudes toward screening for fragile X.

Authors:  Kruti Acharya; Abigail Schindler
Journal:  Am J Intellect Dev Disabil       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.